Over 10 years lat­er, FDA of­fi­cial­ly pulls a BMS ac­cel­er­at­ed ap­proval, and a Te­va copy­cat falls with it

While for­mal­ly an­nounc­ing the with­draw­al of the pe­riph­er­al T-cell lym­phoma (PT­CL) in­di­ca­tion for Bris­tol My­ers Squibb’s Is­to­dax (ro­midepsin) for in­jec­tion (the com­pa­ny made a sim­i­lar …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER